News | August 04, 2022
Sandu Pharmaceuticals launches Sandu Kumarvin
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
Biopharma and CROs to benefit from simplified access to global research sites
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
With this, the company can start selling Ibuprofen in the European markets.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Subscribe To Our Newsletter & Stay Updated
